MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14728222.2022.2170781

Медицинская библиотека · Expert opinion on therapeutic targets · 2023

The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies.

Sadeghi Mohammad, Khodakarami Atefeh, Ahmadi Armin, Fathi Mehrdad, Gholizadeh Navashenaq Jamshid, Mohammadi Hamed, Yousefi Mehdi, Hojjat-Farsangi Mohammad, Movasaghpour Akbari Ali Akbar, Jadidi-Niaragh Farhad

ОбзорСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

INTRODUCTION

Hematological Malignancies (HMs) are a group of progressive, difficult-to-treat, and highly recurrent diseases. A suppressed phenotype of the immune system is present in HMs and growing evidence indicates the role of Cytotoxic T lymphocyte-Associated protein 4 (CTLA-4) in the course of HMs.

AREAS COVERED: This article reviews the recent literature on the role of CTLA-4 in different subtypes of HMs. Here, the studies on the expression pattern, its effect on the prognosis of different HMs, and polymorphisms of CTLA-4 have been elaborated. Finally, the effect of targeting CTLA-4 in vitro and in vivo, as well as in clinical trials, is discussed.

EXPERT OPINION: According to the recent literature, CTLA-4 is overexpressed in different HMs, which is correlated with poor survival, while it is associated with better a prognosis in Chronic Lymphocytic Leukemia (CLL). Targeting CTLA-4 in Acute Myeloid Leukemia (AML), Sezary Syndrome (SS), Hodgkin's Lymphoma (HL), and so on, is helpful. While this is not recommended and may even be harmful in multiple myeloma (MM) and CLL. Also, it seems that certain CTLA-4 gene polymorphisms are efficient factors in the course of HMs. Future studies may broaden our knowledge regarding the role of CTLA-4 in HMs.

Для цитирования: Sadeghi Mohammad, Khodakarami Atefeh, Ahmadi Armin, Fathi Mehrdad, Gholizadeh Navashenaq Jamshid, Mohammadi Hamed, Yousefi Mehdi, Hojjat-Farsangi Mohammad, Movasaghpour Akbari Ali Akbar, Jadidi-Niaragh Farhad. The prognostic and therapeutic potentials of CTLA-4 in hematological malignancies.. Expert opinion on therapeutic targets. 2023. DOI: 10.1080/14728222.2022.2170781.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.